Abstract
A phase 1-2 trial of selpercatinib showed durable efficacy with mainly low-grade toxicity in patients with medullary thyroid cancer (MTC) with and without previous treatment with cabozantinib or vandetanib. Complete response was observed in 5 of 55 previously treated and in 10 of 88 not previously treated patients. We report a 58-year-old patient with total thyroidectomy for a 3 cm Ret C634R positive MTC with 16 of 28 resected lymph nodes positive, largest deposit 2.1 cm. Metastatic MTC with several up to 6 mm large biopsy proven liver and a PETCT intensely enhancing 8 mm C6 bone metastasis were diagnosed 14 and 40 months after total thyroidectomy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
